葡萄糖皮质激素不敏感:这是时间和地点的问题吗?
Christopher Lambers1, Michael Roth2
1Department Pneumology, Ordensklinikum Linz Elisabethinen, AT-4020 Linz, Austria.
Biomedicines
|June 26, 2025
概括
在喘和COPD中,葡萄糖皮质体不敏感会限制治疗的有效性. 未来的研究应该探索葡萄糖皮质体信号通路在各种条件中的动态相互作用.
科学领域:
- 肺部医学 肺部医学
- 分子生物学分子生物学
- 药物基因组学 药物基因组学
背景情况:
- 葡萄糖皮质类药物不敏感性在慢性炎症性肺部疾病 (如喘和COPD) 中构成治疗挑战.
- 目前的治疗方法只能提供症状缓解,患者对葡萄糖皮质激素的反应是可变的.
- 葡萄糖皮质体受体 (GR) 途径复杂,涉及基因多态,蛋白质异型和翻译后修改,影响治疗结果.
研究的目的:
- 突出葡萄糖皮质体受体 (GR) 功能的复杂性及其对治疗不敏感性的影响.
- 强调需要全面了解慢性炎症肺部疾病中GR信号级联的需要.
主要方法:
- 对有关葡萄糖皮质体受体 (GR) 遗传学,异构体和功能的现有文献的综述.
- 分析导致患者可变葡萄糖皮质激素反应的因素.
- 讨论目前评估GR功能的方法的局限性.
主要成果:
- 在NR3C1基因中,有超过3000个单核酸多态,有助于GR多样性.
- 多个GR蛋白异型由替代转录起点和mRNA拼接产生的.
- 细胞类型特异性,亚细胞局部化和翻译后修饰进一步使GR功能和反应多样化.
结论:
- 未来的研究必须调查GR信号组件的可用性,活动和相互作用的动态时间.
- 使用多种omics方法对健康和患病个体之间的比较分析至关重要.
- 需要对葡萄糖皮质体信号级联的整体看法,以解决肺部疾病中的治疗不敏感性.
相关概念视频
Desensitization and Tachyphylaxis
2.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
399
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
399
Hypoglycemia and Glucagon
351
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
351
Adrenal Gland Disorders
1.9K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.9K
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
GPCR Desensitization
6.6K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.6K


